XTX Topco’s Terns Pharmaceuticals TERN Stock Holding History

XTX Topco’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,032	Closed	-$688K	–	4383
2025 Q4	$688K	Buy	+17,032	New	+$394K	0.02%	1331
2025 Q3	–	Sell	-29,515	Closed	-$110K	–	3262
2025 Q2	$110K	Buy	+29,515	New	+$92.2K	﹤0.01%	1866
2024 Q4	–	Sell	-17,696	Closed	-$148K	–	2925
2024 Q3	$148K	Buy	+17,696	New	+$146K	0.01%	1531
2023 Q4	–	Sell	-33,055	Closed	-$166K	–	2136
2023 Q3	$166K	Sell	33,055 -8,426	-20%	-$53.5K	0.03%	1076
2023 Q2	$363K	Buy	+41,481	New	+$483K	0.07%	579

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

XTX Topco's TERN Position: Q1 2026 in Review

XTX Topco sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 17,032 shares — an estimated $688K sold.

XTX Topco first reported a position in TERN in Q2 2023 and held it in 5 quarters. The position peaked at $688K in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

XTX Topco reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
XTX Topco sold 17,032 Terns Pharmaceuticals shares in Q1 2026, an estimated $688K.
XTX Topco first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 5 quarters.
XTX Topco's Terns Pharmaceuticals position peaked at $688K in Q4 2025.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.